{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"17"}]}],"title":"Increase from Baseline to any grade"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"title":"Increase from Baseline to Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Increase from Baseline to Grade 3/4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"description":"An increase in the QTc interval corrected using Bazett's formula (Bazett's QTc) was recorded for all treated participants. Grade 1 (450-480 milliseconds \\[msec\\]), Grade 2 (481-500 msec), Grade 3/4 (\\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade.","groups":[{"description":"Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.","id":"OG000","title":"GSK2118436 150 mg: No Prior Local Therapy"},{"description":"Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.","id":"OG001","title":"GSK2118436 150 mg: Prior Local Therapy"}],"paramType":"NUMBER","populationDescription":"ATS Population. Only those participants with data available at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline; Weeks 4, 12, 20, 28, 40, 52, and 64","title":"Number of Participants With a Worst-case On-therapy Increase From Baseline in Bazett's QTc Reading in the 12-lead Electrocardiogram (ECG)","type":"SECONDARY","unitOfMeasure":"participants"}